PMID: 24819116
Authors:
Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, Cui JJ, Deal JG, Deng YL, Dinh DM, Engstrom LD, He M, Hoffman JE, Hoffman RL, Huang Q, Kath J, Kania RS, Lam H, Lam JL, Le PT, Lingardo L, Liu W, McTigue MA, Palmer CL, Sach NW, Smeal T, Smith GL, Stewart AE, Timofeevski SL, Zhu H, Zhu J, Zou HY, Edwards MP
Title:
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of ALK/ROS1 with pre-clinical brain exposure and broad spectrum potency against ALK-resistant mutations.
Journal:
J Med Chem. 2014 May 13.
Abstract:
Although crizotinib demonstrates robust efficacy in ALK positive NSCLC patients, progression during treatment eventually develops. Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation. In addition, some patients progress due to cancer metastasis in the brain. Using structure based drug design, LipE, and physical property based optimization, highly potent macrocyclic ALK inhibitors were prepared with good ADME, low propensity for Pgp-mediated efflux and good passive permeability. These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clinically reported ALK kinase domain mutations. Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms. This work led to the discovery of 8k (PF-06463922), combining broad spectrum potency, CNS ADME and a high degree of kinase selectivity.